PSTX News and Press, Poseida Therapeutics Inc. From 03/19/24

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference PR Newswire SAN DIEGO , March 19, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatme...

2024-03-17 00:40:48 ET Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is ...

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma PR Newswire Data Describing Activity of P-BCMA-ALLO1 in BCMA-Experienced Patients to be Presented at Upcoming AACR Meeting SAN DIEGO , Mar...

2024-03-13 08:22:59 ET More on Poseida Therapeutics Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics Financial informa...

2024-03-11 12:49:34 ET Gainers: Kidpik Corp ( PIK ) +118% . TC BioPharm ( TCBP ) +94% . L.S. Starrett Co. ( SCX ) +59% . Kingsoft Cloud Holdings Ltd ( KC ) +33% . Energem Corp ( ENCP ) +31% . NextNav ( NN ) +28% . ...

2024-03-07 17:16:08 ET More on Poseida Therapeutics Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics Financial informa...

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 PR Newswire Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initia...

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones PR Newswire Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of T SCM -rich allogeneic CAR-T to ...

2023-12-21 08:06:15 ET Summary Poseida Therapeutics is an oncology-focused biotech specializing in the development of cell therapies, particularly CAR T-cell approaches for multiple myeloma and acute leukemia. They have demonstrated promising early results in their clinical trials...

2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...